Proactive Investors - Run By Investors For Investors

Arix Bioscience boost after Harpoon NASDAQ float

The fair value of the company's investment in Harpoon has grown by £6.2mln
dna strands
This is the fourth Arix portfolio company in three years to find its way onto the public markets

Healthcare investment company Arix Bioscience Plc (LON:ARIX) said a fourth portfolio company is listing on the stock market, increasing the valuation of its shareholding.

Harpoon Therapeutics, which is developing T-cell immunotherapies for cancer, is raising £58.4mln from the NASDAQ float.

READ: Arix Bioscience portfolio firm Harpoon Therapeutics plans US IPO

Arix has followed its money by ploughing £4.6mln into the IPO. This takes its stake to 12.1%, which is worth £31.3mln, which includes a boost to the fair value of the original holding of £6.2mln.

“Coupled with its scientific expertise and strong management team, we believe Harpoon is well-positioned to play a significant role in immuno-oncology,” said chief investment officer Joe Anderson.

“As early investors in Harpoon, we are excited to see the potential of the company continue to grow.”

View full ARIX profile View Profile

Arix Bioscience PLC Timeline

Related Articles

November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
April 12 2019
The biotechnology company is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused by chronic naproxen use
April 02 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has made significant progress since it started trading on NEX.

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use